Management of Anticoagulation in Patients with Atrial Fibrillation on DOACs

Core Management Principles

The European Society of Cardiology recommends continuing DOAC therapy indefinitely for stroke prevention in patients with atrial fibrillation and elevated thromboembolic risk, using DOAC-specific dose-reduction criteria when applicable, and avoiding arbitrary dose reductions or switching without clear indication 1
DOACs are the preferred anticoagulant over warfarin for eligible patients with atrial fibrillation to prevent stroke and systemic embolism, offering a 50% reduction in intracranial hemorrhage risk compared to vitamin K antagonists 1, 2
Anticoagulation should be continued long-term in patients with CHA₂DS₂-VASc score ≥2 (men) or ≥3 (women) unless contraindications develop 1
The American College of Cardiology recommends re-evaluating the need for anticoagulation at regular intervals to assess ongoing risk-benefit balance 3, 4

Reduced-dose DOAC therapy is NOT recommended unless patients meet specific DOAC-specific criteria to prevent underdosing and avoidable thromboembolic events 1
For apixaban, the American Heart Association recommends reducing to 2.5 mg twice daily only if patient meets ≥2 of these criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥133 μmol/L (1.5 mg/dL) 2
For rivaroxaban, the European Society of Cardiology recommends dose adjustment based on creatinine clearance per drug-specific labeling 2

The American College of Cardiology recommends assessing renal function before initiating any DOAC and monitoring regularly during treatment as DOACs have varying degrees of renal elimination 2, 5, 6
Frequency of renal monitoring should increase with age ≥75 years, declining renal function, or concurrent nephrotoxic medications 2

The European Society of Cardiology recommends evaluating potential drug interactions with current medications, particularly diltiazem, verapamil, and azole antifungals 2

The American Heart Association recommends avoiding adding antiplatelet therapy to anticoagulation in atrial fibrillation patients for stroke prevention, as it increases bleeding risk without reducing thromboembolism 1, 5, 6
Switching from one DOAC to another, or from DOAC to warfarin, without clear indication is NOT recommended to prevent recurrent embolic stroke 1

The European Society of Cardiology recommends using warfarin instead of DOACs in patients with mechanical prosthetic heart valves, moderate-to-severe mitral stenosis, and triple-positive antiphospholipid syndrome 1, 2
Bioprosthetic valves (including TAVR) are compatible with DOAC therapy 2
The American College of Cardiology recommends considering specific reversal agents for life-threatening bleeding or bleeding into critical sites: idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors (apixaban, rivaroxaban) 1, 2

The European Society of Cardiology recommends that DOACs can be temporarily discontinued without bridging therapy for planned procedures, unlike warfarin which often requires heparin bridging 2
Timing of discontinuation depends on renal function and bleeding risk of the procedure (typically 24-48 hours before high-bleeding-risk procedures) 2